Chris Patil

Good afternoon, and thank you for joining us today for BioAge Labs R&D Day. I'm Chris Patil, VP of Media at BioAge.

Before we begin, I would like to remind everyone that during this call, we will be making forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are based on our current beliefs, plans, expectations and assumptions as of today, and are subject to risks, uncertainties and other factors that could cause actual results to differ materially from those expressed or implied by such statements. These risks and other factors can be found in our most recent annual report on Form 10-K, quarterly reports on Form 10-Q and other filings we have made with the Securities and Exchange Commission. We encourage you to review these filings as well as the full forward-looking statements disclaimer on the next slide for a more complete understanding of the risks associated with our business.

We undertake no obligation to update or revise any forward-looking statement, whether as a result of new information, future events or otherwise, except as required by law. A copy of the presentation materials for today's call are available on the Investor Relations section of our website at ir.bioagelabs.com.

Welcome to BioAge Labs R&D Day. Today, we'll be presenting an update on our lead program, BGE-102, our oral brain-penetrant NLRP3 inhibitor including our Phase I clinical results and our development strategy across cardiovascular